Patient relevant endpoints in oncology: current issues in the context of early benefit assessment in Germany View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2014-12

AUTHORS

Inna Dabisch, Jürgen Dethling, Charalabos-Markos Dintsios, Melanie Drechsler, Daniel Kalanovic, Peter Kaskel, Frank Langer, Jörg Ruof, Thorsten Ruppert, Daniel Wirth

ABSTRACT

The German AMNOG healthcare reform includes a mandatory early-benefit-assessment (EBA) at launch. As per German social code, EBA is based on registration trials and includes evaluation of the patient-relevant effect of the new medicines compared to an appropriate comparator as defined by the Federal Joint Committee (G-BA). Current EBA decisions released have unveiled issues regarding the acceptance of some patient-relevant endpoints as G-BA and IQWiG are grading the endpoints, focusing on overall survival as the preferred endpoint in oncology.A taskforce of experienced German outcomes research, medical, health-technology assessment and biostatistics researchers in industry was appointed. After agreement on core assumptions, a draft position was prepared. Input on iterative versions was solicited from a panel of reviewers from industry and external stakeholders.Distinctive features of registration trials in oncology need to be considered when these studies form basis for EBA, especially in cancer-indications with long post-progression survival; and with several consecutive therapeutic options available post-progression. Ethical committees, caregivers and patients often demand cross-over-designs diluting the treatment-effect on overall survival. Regulatory authorities require evaluation of morbidity-related study endpoints including survival of patients without their disease getting worse (i.e., progression-free survival). Also, progression requires treatment-changes, another strong indicator for its relevance to patients.Based on specific guidelines and clinical trial programs that were developed to be consistent with regulatory guidance, endpoints in oncology are thoroughly evaluated in terms of their patient-relevance. This extensive knowledge and experience should be fully acknowledged during EBA when assessing the patient-relevant benefit of innovative medicines in oncology. JEL CODES: D61; H51; I18. More... »

PAGES

2

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/2191-1991-4-2

DOI

http://dx.doi.org/10.1186/2191-1991-4-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1016863946

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/24460706


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "German Association of Research-based Pharmaceutical Companies (vfa), Berlin, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dabisch", 
        "givenName": "Inna", 
        "id": "sg:person.01074334156.67", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01074334156.67"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "GlaxoSmithKline (Germany)", 
          "id": "https://www.grid.ac/institutes/grid.420105.2", 
          "name": [
            "GlaxoSmithKline GmbH & Co., Munich, KG, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dethling", 
        "givenName": "J\u00fcrgen", 
        "id": "sg:person.01352546532.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01352546532.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "German Association of Research-based Pharmaceutical Companies (vfa), Berlin, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dintsios", 
        "givenName": "Charalabos-Markos", 
        "id": "sg:person.01004341263.95", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01004341263.95"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Boehringer Ingelheim (Germany)", 
          "id": "https://www.grid.ac/institutes/grid.420061.1", 
          "name": [
            "Boehringer Ingelheim Pharma GmbH & Co., Ingelheim, KG, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Drechsler", 
        "givenName": "Melanie", 
        "id": "sg:person.01247654747.73", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01247654747.73"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer (Germany)", 
          "id": "https://www.grid.ac/institutes/grid.476393.c", 
          "name": [
            "Pfizer Pharma GmbH, Berlin, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kalanovic", 
        "givenName": "Daniel", 
        "id": "sg:person.0720442760.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0720442760.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "MSD (Germany)", 
          "id": "https://www.grid.ac/institutes/grid.476255.7", 
          "name": [
            "MSD SHARP & DOHME GMBH, Lindenplatz 1, 85540, Haar, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kaskel", 
        "givenName": "Peter", 
        "id": "sg:person.0773616073.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0773616073.80"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Eli Lilly (Germany)", 
          "id": "https://www.grid.ac/institutes/grid.435900.b", 
          "name": [
            "Lilly Deutschland GmbH, Bad Homburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Langer", 
        "givenName": "Frank", 
        "id": "sg:person.01307316670.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01307316670.12"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche (Germany)", 
          "id": "https://www.grid.ac/institutes/grid.424277.0", 
          "name": [
            "Roche Pharma AG, Grenzach-Wyhlen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ruof", 
        "givenName": "J\u00f6rg", 
        "id": "sg:person.01246054426.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01246054426.47"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "German Association of Research-based Pharmaceutical Companies (vfa), Berlin, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ruppert", 
        "givenName": "Thorsten", 
        "id": "sg:person.0763746656.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0763746656.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Janssen (Germany)", 
          "id": "https://www.grid.ac/institutes/grid.497524.9", 
          "name": [
            "Janssen-Cilag GmbH, Neuss, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wirth", 
        "givenName": "Daniel", 
        "id": "sg:person.01310476327.89", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01310476327.89"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1200/jco.2007.15.3510", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002585977"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2009.38", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002899527", 
          "https://doi.org/10.1038/leu.2009.38"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2009.38", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002899527", 
          "https://doi.org/10.1038/leu.2009.38"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0959-8049(01)00371-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008444022"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ijc.25423", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008467674"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ijc.25423", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008467674"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6601986", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010709152", 
          "https://doi.org/10.1038/sj.bjc.6601986"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6601986", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010709152", 
          "https://doi.org/10.1038/sj.bjc.6601986"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdr362", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012612445"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1352458512448449", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012944288"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1352458512448449", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012944288"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1352458512448449", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012944288"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/bmj.317.7161.771", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015749208"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.10.8407", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017750913"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.urolonc.2015.03.015", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017967707"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/djp369", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019709167"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1185/030079905x74862", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023303316"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1185/030079905x74862", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023303316"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/djq029", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024607483"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/djq029", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024607483"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2011.39.5558", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025698429"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00120-011-2713-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026621978", 
          "https://doi.org/10.1007/s00120-011-2713-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3747/co.v18is2.941", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030292939"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1464-410x.1999.00202.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030326537"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdj023", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031646383"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10198-010-0218-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035704636", 
          "https://doi.org/10.1007/s10198-010-0218-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdq204", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038028713"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2012.45.9867", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038250497"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.13.6796", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038707957"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1352458512451660", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039600953"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1352458512451660", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039600953"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1352458512451660", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039600953"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.clon.2004.06.023", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042113450"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2011-10-383711", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043265594"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.2013.145", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045286767", 
          "https://doi.org/10.1038/bjc.2013.145"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0277-9536(94)90151-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046445641"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ygyno.2007.06.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048555210"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1752-1947-5-429", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051791591", 
          "https://doi.org/10.1186/1752-1947-5-429"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1634/theoncologist.2010-s1-13", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052046724"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa022457", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052596157"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(11)61613-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052713041"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00520-012-1417-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053663300", 
          "https://doi.org/10.1007/s00520-012-1417-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2003.99.078", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064204090"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2003.99.089", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064204096"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077138395", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078165983", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2012.30.18_suppl.cra4502", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083397220"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2014-12", 
    "datePublishedReg": "2014-12-01", 
    "description": "The German AMNOG healthcare reform includes a mandatory early-benefit-assessment (EBA) at launch. As per German social code, EBA is based on registration trials and includes evaluation of the patient-relevant effect of the new medicines compared to an appropriate comparator as defined by the Federal Joint Committee (G-BA). Current EBA decisions released have unveiled issues regarding the acceptance of some patient-relevant endpoints as G-BA and IQWiG are grading the endpoints, focusing on overall survival as the preferred endpoint in oncology.A taskforce of experienced German outcomes research, medical, health-technology assessment and biostatistics researchers in industry was appointed. After agreement on core assumptions, a draft position was prepared. Input on iterative versions was solicited from a panel of reviewers from industry and external stakeholders.Distinctive features of registration trials in oncology need to be considered when these studies form basis for EBA, especially in cancer-indications with long post-progression survival; and with several consecutive therapeutic options available post-progression. Ethical committees, caregivers and patients often demand cross-over-designs diluting the treatment-effect on overall survival. Regulatory authorities require evaluation of morbidity-related study endpoints including survival of patients without their disease getting worse (i.e., progression-free survival). Also, progression requires treatment-changes, another strong indicator for its relevance to patients.Based on specific guidelines and clinical trial programs that were developed to be consistent with regulatory guidance, endpoints in oncology are thoroughly evaluated in terms of their patient-relevance. This extensive knowledge and experience should be fully acknowledged during EBA when assessing the patient-relevant benefit of innovative medicines in oncology.\nJEL CODES: D61; H51; I18.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/2191-1991-4-2", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1046836", 
        "issn": [
          "2191-1991"
        ], 
        "name": "Health Economics Review", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "4"
      }
    ], 
    "name": "Patient relevant endpoints in oncology: current issues in the context of early benefit assessment in Germany", 
    "pagination": "2", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "5059aedfb2fd46020670ba7fc5137a9a7a6637c4781eb40204db5beb2796f9fe"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "24460706"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101583209"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/2191-1991-4-2"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1016863946"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/2191-1991-4-2", 
      "https://app.dimensions.ai/details/publication/pub.1016863946"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T19:15", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8678_00000549.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1186%2F2191-1991-4-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/2191-1991-4-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/2191-1991-4-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/2191-1991-4-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/2191-1991-4-2'


 

This table displays all metadata directly associated to this object as RDF triples.

274 TRIPLES      21 PREDICATES      67 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/2191-1991-4-2 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author N8d0eac95951f4d23bfd8eb1defc91dbd
4 schema:citation sg:pub.10.1007/s00120-011-2713-5
5 sg:pub.10.1007/s00520-012-1417-8
6 sg:pub.10.1007/s10198-010-0218-6
7 sg:pub.10.1038/bjc.2013.145
8 sg:pub.10.1038/leu.2009.38
9 sg:pub.10.1038/sj.bjc.6601986
10 sg:pub.10.1186/1752-1947-5-429
11 https://app.dimensions.ai/details/publication/pub.1077138395
12 https://app.dimensions.ai/details/publication/pub.1078165983
13 https://doi.org/10.1002/ijc.25423
14 https://doi.org/10.1016/0277-9536(94)90151-1
15 https://doi.org/10.1016/j.clon.2004.06.023
16 https://doi.org/10.1016/j.urolonc.2015.03.015
17 https://doi.org/10.1016/j.ygyno.2007.06.005
18 https://doi.org/10.1016/s0140-6736(11)61613-9
19 https://doi.org/10.1016/s0959-8049(01)00371-9
20 https://doi.org/10.1046/j.1464-410x.1999.00202.x
21 https://doi.org/10.1056/nejmoa022457
22 https://doi.org/10.1093/annonc/mdj023
23 https://doi.org/10.1093/annonc/mdq204
24 https://doi.org/10.1093/annonc/mdr362
25 https://doi.org/10.1093/jnci/djp369
26 https://doi.org/10.1093/jnci/djq029
27 https://doi.org/10.1136/bmj.317.7161.771
28 https://doi.org/10.1177/1352458512448449
29 https://doi.org/10.1177/1352458512451660
30 https://doi.org/10.1182/blood-2011-10-383711
31 https://doi.org/10.1185/030079905x74862
32 https://doi.org/10.1200/jco.2003.99.078
33 https://doi.org/10.1200/jco.2003.99.089
34 https://doi.org/10.1200/jco.2007.10.8407
35 https://doi.org/10.1200/jco.2007.13.6796
36 https://doi.org/10.1200/jco.2007.15.3510
37 https://doi.org/10.1200/jco.2011.39.5558
38 https://doi.org/10.1200/jco.2012.30.18_suppl.cra4502
39 https://doi.org/10.1200/jco.2012.45.9867
40 https://doi.org/10.1634/theoncologist.2010-s1-13
41 https://doi.org/10.3747/co.v18is2.941
42 schema:datePublished 2014-12
43 schema:datePublishedReg 2014-12-01
44 schema:description The German AMNOG healthcare reform includes a mandatory early-benefit-assessment (EBA) at launch. As per German social code, EBA is based on registration trials and includes evaluation of the patient-relevant effect of the new medicines compared to an appropriate comparator as defined by the Federal Joint Committee (G-BA). Current EBA decisions released have unveiled issues regarding the acceptance of some patient-relevant endpoints as G-BA and IQWiG are grading the endpoints, focusing on overall survival as the preferred endpoint in oncology.A taskforce of experienced German outcomes research, medical, health-technology assessment and biostatistics researchers in industry was appointed. After agreement on core assumptions, a draft position was prepared. Input on iterative versions was solicited from a panel of reviewers from industry and external stakeholders.Distinctive features of registration trials in oncology need to be considered when these studies form basis for EBA, especially in cancer-indications with long post-progression survival; and with several consecutive therapeutic options available post-progression. Ethical committees, caregivers and patients often demand cross-over-designs diluting the treatment-effect on overall survival. Regulatory authorities require evaluation of morbidity-related study endpoints including survival of patients without their disease getting worse (i.e., progression-free survival). Also, progression requires treatment-changes, another strong indicator for its relevance to patients.Based on specific guidelines and clinical trial programs that were developed to be consistent with regulatory guidance, endpoints in oncology are thoroughly evaluated in terms of their patient-relevance. This extensive knowledge and experience should be fully acknowledged during EBA when assessing the patient-relevant benefit of innovative medicines in oncology. JEL CODES: D61; H51; I18.
45 schema:genre research_article
46 schema:inLanguage en
47 schema:isAccessibleForFree true
48 schema:isPartOf N65870c594e754cfb969082a0b5d7ff85
49 N794b254828c845b2b3480438b699290c
50 sg:journal.1046836
51 schema:name Patient relevant endpoints in oncology: current issues in the context of early benefit assessment in Germany
52 schema:pagination 2
53 schema:productId N3bf8fdc051a4492ea8cd73edefb567e6
54 N53b77ce418b747afbe39fc9db930e80b
55 N58d9bc43a2424fa892a090a0244ca20a
56 N6e1b4754f179452e8845f421c9142ff2
57 Nb49e906bf4cb4dc0b28ab16f18e7ec8a
58 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016863946
59 https://doi.org/10.1186/2191-1991-4-2
60 schema:sdDatePublished 2019-04-10T19:15
61 schema:sdLicense https://scigraph.springernature.com/explorer/license/
62 schema:sdPublisher N8f72abc845314f648c115664561d6c52
63 schema:url http://link.springer.com/10.1186%2F2191-1991-4-2
64 sgo:license sg:explorer/license/
65 sgo:sdDataset articles
66 rdf:type schema:ScholarlyArticle
67 N014bc4ecda864b97b6f1917e55c187f1 rdf:first sg:person.01246054426.47
68 rdf:rest Nfa9ef97853a346ffa703c7a5cd871804
69 N16a2e4e3dc3d4753bd0014d1abab4962 schema:name German Association of Research-based Pharmaceutical Companies (vfa), Berlin, Germany
70 rdf:type schema:Organization
71 N1b349e5fcfac4207afe4ead38cd11729 rdf:first sg:person.01310476327.89
72 rdf:rest rdf:nil
73 N30a960edba214a01bd73af67723eb72c rdf:first sg:person.0773616073.80
74 rdf:rest N5dbee0cb15964bb9aae05697c07246ad
75 N3bf8fdc051a4492ea8cd73edefb567e6 schema:name doi
76 schema:value 10.1186/2191-1991-4-2
77 rdf:type schema:PropertyValue
78 N53b77ce418b747afbe39fc9db930e80b schema:name dimensions_id
79 schema:value pub.1016863946
80 rdf:type schema:PropertyValue
81 N58d9bc43a2424fa892a090a0244ca20a schema:name readcube_id
82 schema:value 5059aedfb2fd46020670ba7fc5137a9a7a6637c4781eb40204db5beb2796f9fe
83 rdf:type schema:PropertyValue
84 N5969b058288f4c77b93ed4132d2dfd01 schema:name German Association of Research-based Pharmaceutical Companies (vfa), Berlin, Germany
85 rdf:type schema:Organization
86 N5dbee0cb15964bb9aae05697c07246ad rdf:first sg:person.01307316670.12
87 rdf:rest N014bc4ecda864b97b6f1917e55c187f1
88 N65870c594e754cfb969082a0b5d7ff85 schema:volumeNumber 4
89 rdf:type schema:PublicationVolume
90 N6e1b4754f179452e8845f421c9142ff2 schema:name nlm_unique_id
91 schema:value 101583209
92 rdf:type schema:PropertyValue
93 N73c88fe9d9a74481b6ed2c3a8bba801f rdf:first sg:person.0720442760.21
94 rdf:rest N30a960edba214a01bd73af67723eb72c
95 N794b254828c845b2b3480438b699290c schema:issueNumber 1
96 rdf:type schema:PublicationIssue
97 N7e6fcc79586c47db88c5cfe27b420171 rdf:first sg:person.01004341263.95
98 rdf:rest Nf1e12bba914c4970b7e07ffbc0e7ef54
99 N8d0eac95951f4d23bfd8eb1defc91dbd rdf:first sg:person.01074334156.67
100 rdf:rest Nac82ff150e204b5f91de36edd90f04ce
101 N8f72abc845314f648c115664561d6c52 schema:name Springer Nature - SN SciGraph project
102 rdf:type schema:Organization
103 Nac82ff150e204b5f91de36edd90f04ce rdf:first sg:person.01352546532.30
104 rdf:rest N7e6fcc79586c47db88c5cfe27b420171
105 Nb49e906bf4cb4dc0b28ab16f18e7ec8a schema:name pubmed_id
106 schema:value 24460706
107 rdf:type schema:PropertyValue
108 Ne16d89a8d3de4279912904ab75e00f23 schema:name German Association of Research-based Pharmaceutical Companies (vfa), Berlin, Germany
109 rdf:type schema:Organization
110 Nf1e12bba914c4970b7e07ffbc0e7ef54 rdf:first sg:person.01247654747.73
111 rdf:rest N73c88fe9d9a74481b6ed2c3a8bba801f
112 Nfa9ef97853a346ffa703c7a5cd871804 rdf:first sg:person.0763746656.45
113 rdf:rest N1b349e5fcfac4207afe4ead38cd11729
114 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
115 schema:name Medical and Health Sciences
116 rdf:type schema:DefinedTerm
117 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
118 schema:name Oncology and Carcinogenesis
119 rdf:type schema:DefinedTerm
120 sg:journal.1046836 schema:issn 2191-1991
121 schema:name Health Economics Review
122 rdf:type schema:Periodical
123 sg:person.01004341263.95 schema:affiliation Ne16d89a8d3de4279912904ab75e00f23
124 schema:familyName Dintsios
125 schema:givenName Charalabos-Markos
126 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01004341263.95
127 rdf:type schema:Person
128 sg:person.01074334156.67 schema:affiliation N16a2e4e3dc3d4753bd0014d1abab4962
129 schema:familyName Dabisch
130 schema:givenName Inna
131 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01074334156.67
132 rdf:type schema:Person
133 sg:person.01246054426.47 schema:affiliation https://www.grid.ac/institutes/grid.424277.0
134 schema:familyName Ruof
135 schema:givenName Jörg
136 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01246054426.47
137 rdf:type schema:Person
138 sg:person.01247654747.73 schema:affiliation https://www.grid.ac/institutes/grid.420061.1
139 schema:familyName Drechsler
140 schema:givenName Melanie
141 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01247654747.73
142 rdf:type schema:Person
143 sg:person.01307316670.12 schema:affiliation https://www.grid.ac/institutes/grid.435900.b
144 schema:familyName Langer
145 schema:givenName Frank
146 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01307316670.12
147 rdf:type schema:Person
148 sg:person.01310476327.89 schema:affiliation https://www.grid.ac/institutes/grid.497524.9
149 schema:familyName Wirth
150 schema:givenName Daniel
151 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01310476327.89
152 rdf:type schema:Person
153 sg:person.01352546532.30 schema:affiliation https://www.grid.ac/institutes/grid.420105.2
154 schema:familyName Dethling
155 schema:givenName Jürgen
156 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01352546532.30
157 rdf:type schema:Person
158 sg:person.0720442760.21 schema:affiliation https://www.grid.ac/institutes/grid.476393.c
159 schema:familyName Kalanovic
160 schema:givenName Daniel
161 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0720442760.21
162 rdf:type schema:Person
163 sg:person.0763746656.45 schema:affiliation N5969b058288f4c77b93ed4132d2dfd01
164 schema:familyName Ruppert
165 schema:givenName Thorsten
166 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0763746656.45
167 rdf:type schema:Person
168 sg:person.0773616073.80 schema:affiliation https://www.grid.ac/institutes/grid.476255.7
169 schema:familyName Kaskel
170 schema:givenName Peter
171 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0773616073.80
172 rdf:type schema:Person
173 sg:pub.10.1007/s00120-011-2713-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026621978
174 https://doi.org/10.1007/s00120-011-2713-5
175 rdf:type schema:CreativeWork
176 sg:pub.10.1007/s00520-012-1417-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053663300
177 https://doi.org/10.1007/s00520-012-1417-8
178 rdf:type schema:CreativeWork
179 sg:pub.10.1007/s10198-010-0218-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035704636
180 https://doi.org/10.1007/s10198-010-0218-6
181 rdf:type schema:CreativeWork
182 sg:pub.10.1038/bjc.2013.145 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045286767
183 https://doi.org/10.1038/bjc.2013.145
184 rdf:type schema:CreativeWork
185 sg:pub.10.1038/leu.2009.38 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002899527
186 https://doi.org/10.1038/leu.2009.38
187 rdf:type schema:CreativeWork
188 sg:pub.10.1038/sj.bjc.6601986 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010709152
189 https://doi.org/10.1038/sj.bjc.6601986
190 rdf:type schema:CreativeWork
191 sg:pub.10.1186/1752-1947-5-429 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051791591
192 https://doi.org/10.1186/1752-1947-5-429
193 rdf:type schema:CreativeWork
194 https://app.dimensions.ai/details/publication/pub.1077138395 schema:CreativeWork
195 https://app.dimensions.ai/details/publication/pub.1078165983 schema:CreativeWork
196 https://doi.org/10.1002/ijc.25423 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008467674
197 rdf:type schema:CreativeWork
198 https://doi.org/10.1016/0277-9536(94)90151-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046445641
199 rdf:type schema:CreativeWork
200 https://doi.org/10.1016/j.clon.2004.06.023 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042113450
201 rdf:type schema:CreativeWork
202 https://doi.org/10.1016/j.urolonc.2015.03.015 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017967707
203 rdf:type schema:CreativeWork
204 https://doi.org/10.1016/j.ygyno.2007.06.005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048555210
205 rdf:type schema:CreativeWork
206 https://doi.org/10.1016/s0140-6736(11)61613-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052713041
207 rdf:type schema:CreativeWork
208 https://doi.org/10.1016/s0959-8049(01)00371-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008444022
209 rdf:type schema:CreativeWork
210 https://doi.org/10.1046/j.1464-410x.1999.00202.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1030326537
211 rdf:type schema:CreativeWork
212 https://doi.org/10.1056/nejmoa022457 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052596157
213 rdf:type schema:CreativeWork
214 https://doi.org/10.1093/annonc/mdj023 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031646383
215 rdf:type schema:CreativeWork
216 https://doi.org/10.1093/annonc/mdq204 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038028713
217 rdf:type schema:CreativeWork
218 https://doi.org/10.1093/annonc/mdr362 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012612445
219 rdf:type schema:CreativeWork
220 https://doi.org/10.1093/jnci/djp369 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019709167
221 rdf:type schema:CreativeWork
222 https://doi.org/10.1093/jnci/djq029 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024607483
223 rdf:type schema:CreativeWork
224 https://doi.org/10.1136/bmj.317.7161.771 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015749208
225 rdf:type schema:CreativeWork
226 https://doi.org/10.1177/1352458512448449 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012944288
227 rdf:type schema:CreativeWork
228 https://doi.org/10.1177/1352458512451660 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039600953
229 rdf:type schema:CreativeWork
230 https://doi.org/10.1182/blood-2011-10-383711 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043265594
231 rdf:type schema:CreativeWork
232 https://doi.org/10.1185/030079905x74862 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023303316
233 rdf:type schema:CreativeWork
234 https://doi.org/10.1200/jco.2003.99.078 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064204090
235 rdf:type schema:CreativeWork
236 https://doi.org/10.1200/jco.2003.99.089 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064204096
237 rdf:type schema:CreativeWork
238 https://doi.org/10.1200/jco.2007.10.8407 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017750913
239 rdf:type schema:CreativeWork
240 https://doi.org/10.1200/jco.2007.13.6796 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038707957
241 rdf:type schema:CreativeWork
242 https://doi.org/10.1200/jco.2007.15.3510 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002585977
243 rdf:type schema:CreativeWork
244 https://doi.org/10.1200/jco.2011.39.5558 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025698429
245 rdf:type schema:CreativeWork
246 https://doi.org/10.1200/jco.2012.30.18_suppl.cra4502 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083397220
247 rdf:type schema:CreativeWork
248 https://doi.org/10.1200/jco.2012.45.9867 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038250497
249 rdf:type schema:CreativeWork
250 https://doi.org/10.1634/theoncologist.2010-s1-13 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052046724
251 rdf:type schema:CreativeWork
252 https://doi.org/10.3747/co.v18is2.941 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030292939
253 rdf:type schema:CreativeWork
254 https://www.grid.ac/institutes/grid.420061.1 schema:alternateName Boehringer Ingelheim (Germany)
255 schema:name Boehringer Ingelheim Pharma GmbH & Co., Ingelheim, KG, Germany
256 rdf:type schema:Organization
257 https://www.grid.ac/institutes/grid.420105.2 schema:alternateName GlaxoSmithKline (Germany)
258 schema:name GlaxoSmithKline GmbH & Co., Munich, KG, Germany
259 rdf:type schema:Organization
260 https://www.grid.ac/institutes/grid.424277.0 schema:alternateName Roche (Germany)
261 schema:name Roche Pharma AG, Grenzach-Wyhlen, Germany
262 rdf:type schema:Organization
263 https://www.grid.ac/institutes/grid.435900.b schema:alternateName Eli Lilly (Germany)
264 schema:name Lilly Deutschland GmbH, Bad Homburg, Germany
265 rdf:type schema:Organization
266 https://www.grid.ac/institutes/grid.476255.7 schema:alternateName MSD (Germany)
267 schema:name MSD SHARP & DOHME GMBH, Lindenplatz 1, 85540, Haar, Germany
268 rdf:type schema:Organization
269 https://www.grid.ac/institutes/grid.476393.c schema:alternateName Pfizer (Germany)
270 schema:name Pfizer Pharma GmbH, Berlin, Germany
271 rdf:type schema:Organization
272 https://www.grid.ac/institutes/grid.497524.9 schema:alternateName Janssen (Germany)
273 schema:name Janssen-Cilag GmbH, Neuss, Germany
274 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...